← Eichor
Study identifier: NCT07226674 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Microbiota Mediated Flavonoid Metabolites for Cognitive Health

Condition: Cognitive Decline · Cognitive Dysfunction  ·  Sponsor: University of Ulster

PhaseNA
Planned participants100
Who can joinAll sexes, 50 Years to no upper limit
Healthy volunteersYes

About this study

Globally, populations are ageing increasing the prevalence of Alzheimer's disease (AD), due to lack of effective treatments. The traditional Mediterranean diet, rich in fibre and polyphenols (PPs) can help prevent or delay cognitive dysfunction and preserve healthy brain structure and function. Cognitive decline is inversely associated with higher PP intakes (\>421mg/day) i.e., total flavonoids, flavan-3-ols and flavonoid oligomers. The positive brain effects of flavonoid intake are likely mediated in part by gut microbial PP metabolites, consistent with the emerging role of the brain-gut microbiome (BGM) system in neurodegeneration. Our preliminary data indicate that circulating phenyl-γ-valerolactones (PVL), neuroprotective compounds exclusively produced by gut microbiota from flavan-3-ol rich foods18 are associated with delaying cognitive dysfunction. Intake of PPs change gut microbial composition and function, altering the physiology of the host's secondary bile acid (BA) pool through modulation of bacterial 7α-dehydroxylation of de-conjugated primary BAs into secondary BAs. This is noteworthy as 7α-dehydroxylation of BAs does not happen in the brain and because gut microbial BA metabolites have regulatory and signalling functions in the brain. The ratio between certain primary and secondary BAs is also dysregulated in AD with significantly lower serum concentrations of cholic acid (a primary BA) and increased levels of deoxycholic acid (a bacterially produced secondary B…

This description comes directly from the study's public registry record.

Talk to the study team

Chris Gill, PhD  ·  +44 28 7012 3181  ·  c.gill@ulster.ac.uk

Aoife Caffrey, PhD  ·  +44 (0) 28 701 23401  ·  a.caffrey@ulster.ac.uk

Always discuss trial participation with your own doctor first.

Locations (1)

Ulster University, Human Intervention Studies UnitColeraine, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07226674